Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount

Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.

Dermatology Research and Development Strategies Market Access
Advertisement

Market Access

Set Alert for Market Access

Latest From Market Access

Mysterious Amazon/Berkshire/JPMorgan Partnership Could Disrupt Health Care, Pharma

The collective bargaining power of the three large employers, potentially assisted by Amazon's low-cost distribution channels, could be a formidable force in negotiating lower cost and better quality health care services, including pharmaceutical products.

Business Strategies Pricing Debate

Braeburn's Buprenorphine Bid: Eight Dosing Options Part Of "All Hands On Deck" Approach

With an FDA decision on its buprenorphine injection expected by Jan. 19, Scrip spoke with Braeburn executives at J.P. Morgan about the company's justification for four once-weekly and four once-monthly doses, competition in the opioid use disorder (OUD) market and the need for more OUD therapies.

Approvals Business Strategies

Pharma Justifies Steep Prices, Plans Fancy Footwork In The Era Of Cures

BioMarin CMO Geoff Nichol envisions "fancy footwork" in future payer negotiations for groundbreaking hemophilia therapy, during a discussion on value at the 2018 Biotech Showcase meeting, held in conjunction with the J.P. Morgan conference.

Regenerative Medicine Pricing Strategies

Express Scripts CEO: “I Don’t Mind If Amazon Comes In”

The pharmacy benefit manager had a rosy view at the J.P. Morgan conference on the online retailer potentially entering the drug distribution market. That may be because CEO Wentworth views them as a partner.

Pharmacy Benefit Management Distribution

The First US Gene Therapy Maker Innovates On Pricing And Reimbursement

Spark priced the gene therapy Luxturna for inherited blindness at $850,000 for treatment of both eyes, below the $1m price some expected, and revealed pioneering market access plans. CEO Jeffrey Marrazzo and Harvard Pilgrim's Michael Sherman talked with Scrip about the details.

Ophthalmic Pricing Strategies

Go Local And Stay Flexible: Unlocking Market Access For Novel Drugs In China

Although regulatory improvement in China has raised hopes that more novel drugs will enter the market, a lack of reimbursement and rounds of price negotiations still pose challenges. A recent report sheds lights on some remedies for policy makers and drug makers.

Market Access Reimbursement
See All
UsernamePublicRestriction

Register